Neurocrine Biosciences is developing INGREZZA for Huntington's disease, utilizing Kinect data in the KINECT-HD study.
1 report, 0 independent
Updated Jun 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Neurocrine Biosciences is developing INGREZZA for Huntington's disease, utilizing Kinect data in the KINECT-HD study.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.
-
Huntington
station on the Long Island Rail Road in New York, USA
Nothing else this week.
Coverage
Newest first; wire copies grouped- Unknown outlet